| ![](/images/empty_line.GIF) |
| |
| |
| |
| |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:Q53FP2 | novel acetylcholine receptor chaperone (human) | | | ![](/images/empty_line.GIF) | | |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:Q53FP2-1 | novel acetylcholine receptor chaperone isoform 1 (human) | | | ![](/images/empty_line.GIF) | | |
| |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:Q53FP2 | novel acetylcholine receptor chaperone (human) | | | ![](/images/empty_line.GIF) | | |
![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) | ![](/images/empty_line.GIF) |
![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) ![](/images/empty_line.GIF) |
PR:Q53FP2-1 | novel acetylcholine receptor chaperone isoform 1 (human) | | | ![](/images/empty_line.GIF) | | |